Evidence map›Paper›PMID 42811461›Full record

ArticleClinical pharmacology in drug development2026

Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions Between Cofrogliptin and Metformin in Healthy Subjects: A Single-Center, Single-Arm, Phase I Study in China.

Cheng Cui, Na Liu, Chang Chu, Shu Niu, Yang Huang, Fangqiong Li, Yaming Li, Haiyan Li, Dongyang Liu

Abstract readClinical Trial, Phase I
In one paragraph

Article in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Cheng Cui *Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Na Liu *Clinical Research Center, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), Beijing, China.
Chang ChuHaisco Pharmaceutical Group Co., Ltd, Chengdu, China.
Shu NiuDrug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Yang HuangClinical Research Center, Beijing Haidian Hospital (Haidian Section of Peking University Third Hospital), Beijing, China.
Fangqiong LiHaisco Pharmaceutical Group Co., Ltd, Chengdu, China.
Yaming LiHaisco Pharmaceutical Group Co., Ltd, Chengdu, China.
Haiyan Li *Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Dongyang Liu *Drug Clinical Trial Center, Department of Pharmacy, Peking University Third Hospital, Beijing, China.

Funding

Haisco Pharmaceutical Group Co. Ltd
6 · The paper itself

Abstract

This single-center, single-arm, Phase I study evaluated drug-drug interactions (DDIs) between cofrogliptin and metformin in healthy Chinese subjects. Twenty-two subjects sequentially received metformin monotherapy (Days 1-4), cofrogliptin monotherapy (Days 6-34), and combination therapy (Days 38-47). Serial blood/urine samples were collected for pharmacokinetic (PK) and pharmacodynamic (PD) analyses. Cofrogliptin showed no significant impact on metformin's PK and PD properties: the geometric mean ratios (GMRs, metformin + cofrogliptin/metformin) with 90% confidence intervals (CIs) for metformin AUC

Indexed as

Dipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetforminAdultArea Under CurveBlood GlucoseChinaDrug InteractionsDrug Therapy, CombinationFemaleHealthy VolunteersHumansMaleYoung AdultBlood GlucoseDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetformincofrogliptinDPP‐4drug interactionmetforminpharmacodynamicspharmacokinetics

Identifiers

PMID42811461
PMCPMC13624280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.